Results

1–10 of 396 results for AMD

OTX-TKI for the Treatment of Neovascular Age-related Macular Degeneration 12-Month Results From a US Clinical Trial
Robert L. Avery, MD
Annual Meeting Talks
2023
Efficacy and Safety of Anti-High Temperature Requirement A1 aHtrA1 Fab in Geographic Atrophy GA Secondary to AMD GAllego Phase 2 Randomized Trial
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2023
The PRIMA Bionic Vision System in Patients With Geographic Atrophy
Lisa C. Olmos de Koo, MD, MBA
Annual Meeting Talks
2023
12-Month Ocular Pharmacokinetic Study of EYP-1901 a Sustained-Release Intravitreal Formulation of the Tyrosine Kinase Inhibitor Vorolanib
Rishi P. Singh, MD
Annual Meeting Talks
2023
Intended vs Actual Intervals Between Intravitreal Anti-VEGF Injections and Assessment of Treatment Delays
Christina Y Weng, MD, MBA, FASRS
Annual Meeting Talks
2023
Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study
Emmanuel Chang, MD PhD FACS FASRS
Annual Meeting Talks
2023
Early Treatment Patterns and Outcomes in Patients With Neovascular Age-Related Macular Degeneration Initiating Faricimab: The FARETINA-AMD Study
Theodore Leng, MD, MS, FASRS
Annual Meeting Talks
2023
Faricimab Rapidly Improves Fluid Parameters in Patients With nAMD
Nikolas JS London, MD, FACS, FASRS
Annual Meeting Talks
2023
Additional Visual and Anatomic Outcomes of Intravitreal Aflibercept Injection, 8 mg vs 2 mg: Post Hoc Analysis of the Phase 2 CANDELA Study
Priya Sharma Vakharia, MD
Annual Meeting Talks
2023
Exudative Age-Related Macular Degeneration Events from the OAKS and DERBY Clinical Trials of Pegcetacoplan in Geographic Atrophy
Roger A. Goldberg, MD, MBA
Annual Meeting Talks
2023